TY - JOUR
T1 - Diagnostic performance of Mac-2-binding protein glycosylation isomer (M2BPGi) as a liver fibrosis marker in chronic hepatitis C patients with chronic kidney disease on hemodialysis
AU - Sulaiman, Andri Sanityoso
AU - Hasan, Irsan
AU - Hustrini, Ni Made
AU - Lydia, Aida
AU - Hanifa, Rachmadianti Sukma
AU - Gani, Rino Alvani
N1 - Funding Information:
The author would like to thank the National Institute of Health Research and Development, the Indonesian Ministry of Health, and Sysmex Indonesia for funding the study. Moreover, the author would also extend their gratitude to Raysha Afiff, Pertiwi Puji Lestari, and Dwi Handayu (Hepatobiliary Division, Faculty of Medicine Universitas Indonesia) for their excellent technical assistance on sample collection and processing.
Funding Information:
Andri Sanityoso Sulaiman received research grant from the Ministry of Health of the Republic of Indonesia and Sysmex Indonesia company. The other authors declare no conflict of interest.
Publisher Copyright:
© 2023, The Author(s), under exclusive licence to The Japanese Society of Nephrology.
PY - 2023
Y1 - 2023
N2 - Background/aim: Liver fibrosis assessment is essential to determine the initiation, duration, and evaluation of chronic hepatitis C treatment. Therefore, the study aimed to assess the role of Mac-2-binding protein glycosylation isomer (M2BPGi) as a biomarker to measure liver fibrosis in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. Serum M2BPGi level and transient elastography results were evaluated in 102 chronic hepatitis C patients with CKD on HD, 36 CKD on HD patients, and 48 healthy controls. ROC analysis was conducted to identify the optimal cutoff values to assess significant fibrosis and cirrhosis among chronic hepatitis C patients with CKD on HD. Results: In chronic hepatitis C patients with CKD on HD, the level of serum M2BPGi had a moderately significant correlation with transient elastography (r = 0.447, p < 0.001). The median serum M2BPGi was higher among CKD on HD patients compared to healthy controls (1.260 COI vs. 0.590 COI, p < 0.001) and was even higher in chronic hepatitis C patients with CKD on HD compared to CKD on HD group (2.190 COI vs. 1.260 COI, p < 0.001). It is also increased according to the severity of liver fibrosis: 1.670 COI, 2.020 COI, and 5.065 COI for F0–F1, significant fibrosis, and cirrhosis, respectively. The optimal cutoff values for diagnosing significant fibrosis and cirrhosis were 2.080 and 2.475 COI, respectively. Conclusion: Serum M2BPGi could be a simple and reliable diagnostic tool for evaluating cirrhosis in chronic hepatitis C patients with CKD on HD.
AB - Background/aim: Liver fibrosis assessment is essential to determine the initiation, duration, and evaluation of chronic hepatitis C treatment. Therefore, the study aimed to assess the role of Mac-2-binding protein glycosylation isomer (M2BPGi) as a biomarker to measure liver fibrosis in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. Serum M2BPGi level and transient elastography results were evaluated in 102 chronic hepatitis C patients with CKD on HD, 36 CKD on HD patients, and 48 healthy controls. ROC analysis was conducted to identify the optimal cutoff values to assess significant fibrosis and cirrhosis among chronic hepatitis C patients with CKD on HD. Results: In chronic hepatitis C patients with CKD on HD, the level of serum M2BPGi had a moderately significant correlation with transient elastography (r = 0.447, p < 0.001). The median serum M2BPGi was higher among CKD on HD patients compared to healthy controls (1.260 COI vs. 0.590 COI, p < 0.001) and was even higher in chronic hepatitis C patients with CKD on HD compared to CKD on HD group (2.190 COI vs. 1.260 COI, p < 0.001). It is also increased according to the severity of liver fibrosis: 1.670 COI, 2.020 COI, and 5.065 COI for F0–F1, significant fibrosis, and cirrhosis, respectively. The optimal cutoff values for diagnosing significant fibrosis and cirrhosis were 2.080 and 2.475 COI, respectively. Conclusion: Serum M2BPGi could be a simple and reliable diagnostic tool for evaluating cirrhosis in chronic hepatitis C patients with CKD on HD.
KW - Chronic hepatitis C
KW - Chronic kidney disease
KW - Hemodialysis
KW - M2BPGi
UR - http://www.scopus.com/inward/record.url?scp=85151340307&partnerID=8YFLogxK
U2 - 10.1007/s10157-023-02319-z
DO - 10.1007/s10157-023-02319-z
M3 - Article
C2 - 36995542
AN - SCOPUS:85151340307
SN - 1342-1751
VL - 27
SP - 557
EP - 564
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 6
ER -
